presented data with significant differences in the number of CD3+, CD4+ and CD8+lymphocytes among patients with moderate, severe and critical phenotype, the severity condition was assessed with the Sixth Revised Trial Version of the Novel Coronavirus Pneumonia Diagnosis and Treatment Guidance, Italy (26). This evidence concerns the gene CD8A and susceptibility to pneumonia measurement.